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The reactogenicity and immunogenicity of purified influenza virus hemagglutinin (HA) vaccines adminis-
tered intramuscularly were evaluated in two placebo-controlled clinical trials. A total of 139 healthy young
adults were randomized to receive increasing doses of monovalent influenza A/Taiwan/1/86 (HiN1) virus HA
(range, 0 to 405 ,Ig per dose [study 1]). An additional 139 subjects were given increasing doses of a trivalent
HA vaccine containing equal amounts of A/HlNl virus, AlShanghai/16/89 (H3N2) virus, and influenza
B/Yamagata/16/88 virus HA (range, 0 to 135 ,ug of HA per strain, 0 to 405 ,ug per dose) or a standard dose of
commercial influenza vaccine (study 2). Increasing doses of HA were associated with increasing frequencies of
symptoms at the vaccination site early after vaccination, but all doses were well tolerated. Occurrence of
systemic symptoms was unrelated to dose. Increasing the dose of HA resulted in increasingly higher
postimmunization levels of serum hemagglutination inhibiting and neutralizing antibody levels versus
influenza AIHlNl virus in study 1 (P < 0.05); these enhanced responses persisted for up to 6 months. Nasal
secretory immunoglobulin A and G antibody responses were assessed 2 weeks after immunization with
monovalent HlNl virus HA; the frequencies of significant responses also increased in a dose-related fashion.
Similar increases in serum antibody levels were noted for both AIHlNl and A/H3N2 viruses in study 2. These
data provide a basis for proceeding with the evaluation of high doses of purified HA in the elderly.
Annual immunization with inactivated vaccines is recom-
mended for the prevention of influenza in persons at greatest
risk for severe complications and death associated with influ-
enza virus infections (3). The level of protection against
influenza virus infection conferred by immunization with inac-
tivated vaccine is strongly correlated with the level of serum
antibody produced against circulating influenza virus variants
(7). For this reason, the serum antibody level elicited by
immunization can be used to predict the efficacy of a particular
vaccine.
Commercially available influenza virus vaccines in the
United States currently contain 15 ,ug of hemagglutinin (HA)
of each virus per dose. Whole and split virus vaccines contain-
ing 15 to 20 ,ug of HA per strain in each dose elicit levels of
serum antibody associated with protection in a majority of
susceptible healthy young adults (2, 12). However, this dose of
inactivated vaccine often fails to elicit significant antibody
responses or levels of antibody that are associated with pro-
tection against infections in elderly persons (28).
One approach to improve the efficacy of influenza virus
vaccines is to increase the antibody response by increasing the
dose of antigen. Previous studies with whole virus or detergent-
disrupted subvirion vaccine have indicated that increasing the
dose may result in significantly higher antibody levels, but
higher doses are associated with increased frequencies of local
and/or systemic reactions (1, 19). The objectives of the present
studies were to assess the reactogenicity and immunogenicity
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of increasing doses of highly purified vaccines containing
influenza virus HA in healthy young adults prior to their
evaluation in elderly subjects.
MATERIALS AND METHODS
Vaccines. Purified influenza virus HA and commercial triva-
lent vaccines were generously provided by Connaught Labora-
tories, Inc., Swiftwater, Pa. The experimental HA vaccines
were prepared by bromelain treatment of egg-grown influenza
viruses followed by chromatographic purification. Final puri-
fied HA migrated as a single band by polyacrylamide gel
electrophoresis and failed to elicit antibody to neuraminidase
in immunized animals. Two purified HA vaccines were evalu-
ated in separate clinical studies: monovalent A/Taiwan/1/86
(H1N1) virus HA (study 1) and a trivalent vaccine composed
of three purified HAs [A/Shanghai/16/89 (H3N2) virus, AITai-
wan/1/86 (HlNl) virus, and B/Yamagata/16/88 virus] (study 2).
During study 2, the antigenically identical commercial sub-
virion vaccine was also administered. Placebo for both studies
was sterile saline. Vaccine or placebo was injected as a single
0.5-ml dose into the deltoid muscle.
Clinical procedures. Healthy 18- to 40-year-old adults were
recruited at Texas A&M University. Individuals with acute or
chronic illness or allergy to eggs and those who were pregnant
were excluded. Informed consent was obtained from each
participant in accordance with protocols approved by local
review boards.
All students were screened for the level of serum antibodies
to the test viruses. For study 1, 139 subjects were stratified
according to screening antibody (or prestudy) levels versus
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influenza A/Taiwan (HlNl) virus into two groups: a high-
antibody group (serum HA inhibiting [HAI] titer, .1:16) or a
low-antibody group (serum HAI titer, <1:8, and serum neu-
tralizing antibody, < 1:12). The neutralizing antibody assay was
performed with sera with low HAI antibody levels in order to
select the most susceptible subjects. After stratification, sub-
jects in each antibody group were randomized to receive a 15-,
45-, 135-, or 405-jig dose of purified influenza A/Taiwan virus
HA (monovalent HA). Volunteers in the high-antibody group
were also randomized into an additional placebo arm. Oral
temperature was recorded between 6 and 12 h after inocula-
tion, and subjects were examined 1 and 2 days after injection.
Blood and nasal wash (NW) specimens for antibody assays
were collected before inoculation (preimmunization) and at 2,
4, 14, and 24 weeks after inoculation. For study 1, the average
proportions of subjects donating blood samples at 2, 4, 14, and
24 weeks after immunization were 94, 99, 77, and 78%,
respectively; for study 2, these proportions were 86, 99, 75, and
80%.
For study 2, 139 subjects were stratified into a high-antibody
group [prestudy serum HAI antibody titer, -1:16 versus
A/Taiwan (HlNl) virus and A/Shanghai (H3N2) virus] or a
low-antibody group [serum HAI, <1:8, and lowest available
neutralizing antibody levels versus A/Taiwan (HlNl) virus,
A/Shanghai (H3N2) virus, and/or B/Yamagata virus]. After
stratification, subjects were randomized to receive 15, 45 or
135 jig of HA of each strain in the vaccine administered (a
total of 405 jig of HA in the highest-dose group) or a standard
0.5-ml dose of the commercial trivalent vaccine. An additional
placebo arm was included in the high-antibody group. Moni-
toring was performed as described for study 1. Attempts to
stratify subjects into high- and low-antibody groups on the
basis of their prestudy levels of antibody against the three
vaccine viruses failed to result in clearly differentiated groups
for all viruses; therefore, high- and low- antibody groups were
combined into a single group for the purpose of data analysis.
Laboratory procedures. Tests for HAI and neutralizing
antibodies on serum samples were performed by using previ-
ously described methods (6, 9). For the HAI antibody test,
concentrations of reagents were altered and an erythrocyte
adsorption step was added to permit a starting dilution of 1:4.
Test viruses included A/Taiwan/1/86 (HlNl) virus (studies 1
and 2) and A/Shanghai/16/89 (H3N2) virus and B/Yamagata/
16/88 virus (study 2 only). A fourfold or greater rise in serum
HAI or neutralizing antibody titer was considered significant.
NW antibody assays after inoculation with monovalent
A/Taiwan virus HA or placebo (study 1) were performed by
enzyme-linked immunosorbent assay (ELISA) as described
previously (14). Purified influenza A/Taiwan/1/86 virus HA was
the test antigen. The NW specimens were homogenized,
clarified by centrifugation, and tested without concentration.
NW pairs suitable for assay contained at least 4.0 jig of
immunoglobulin A (IgA) and 0.5 jig of IgG per 0.1 ml in each
specimen and total concentrations of IgA or IgG in paired
specimens that were not more than 10-fold different from each
other, characteristics required to detect and determine the
specificity of an antibody increase. The quantities of total and
HA-specific antibodies were determined by reference to IgA
and IgG standards, and virus-specific antibody was expressed
as a percentage of total IgA or IgG in the sample. A fourfold
or greater rise in the percentage of HA-specific antibody (IgG
or IgA) in nasal secretions represents a significant difference.
Definition of vaccine reactions. Local symptoms (pain
and/or tenderness at the injection site) and systemic symptoms
(feverishness, malaise, myalgia, headache, and nausea) were
graded on a scale of 0 to 3 (0, absent; 1, mild; 2, moderate; 3,
severe) on the basis of the volunteers' opinion. A vaccine
reaction was considered mild if no fever was reported and the
highest sum of systemic or local scores on day 1 or 2 was <3,
with none being severe. Vaccine reactions were considered
moderate if an oral temperature of 100 to 100.9°F (37.8 to
38.27°C) was recorded, or if the highest sum of systemic or
local symptom scores was 4 to 6 on day 1 or 2, with none being
severe. Oral temperature of . 101'F (38.3°C), the sum of
systemic or local symptom scores on day 1 or 2 of 6 or greater,
or any severe local or systemic symptom was defined as a
severe vaccine reaction.
Statistical methods. Differences in proportions were com-
pared by using the chi-square test. The dose response of the
symptom scores was analyzed via linear least-squares regres-
sion, while the dose response for the incidence of fourfold or
greater rises in antibody titer was analyzed with the chi-square
test for linear trend. The antibody titer levels were analyzed on
the log2 scale. The dose-response analyses were all performed
with doses on the log3 scale, such that doses of 15, 45, 135, and
405 jig were considered equidistant. Analyses were performed
with and without the placebo group. For study 1, analyses were
performed both separately for the low- and high-prestudy-
antibody groups and together for the combined groups. Sepa-
rate analyses were done for each postinoculation measurement
time (2, 4, 14, and 24 weeks). Linear least-squares regression
analysis was used to assess the dose response of the antibody
titers. Multiple linear regression analysis was used to assess
directly whether the dose response was affected by the prestudy
antibody titer. Responses to the subvirion vaccine and the
low-dose trivalent HA vaccine (each containing 15 jig ofHA of
three virus strains) in study 2 were compared via Student's t
test. Antibody levels elicited by immunization with the 15-,ug
dose of each HA also were compared with those elicited by
each of the higher doses by using the two-tailed pooled
variance t test. All analyses were performed with commercial
computer programs (BMDP Statistical Software, Inc., Los
Angeles, Calif.).
RESULTS
Reactogenicity. Injection site and systemic symptoms and
signs recorded during the first 2 days after immunization with
influenza virus vaccines or placebo are summarized in Table 1.
A report of mild or moderate pain and/or tenderness at the site
of inoculation was common, even with the placebo, and the
frequency increased with increasing doses of purified HA in
both studies. Erythema and/or induration -5 mm in diameter
was observed in 3 (12%) of the subjects given the highest dose
of monovalent HA. Four to 14% of subjects given trivalent HA
developed redness or swelling; no clear dose-related increase
in these reactions was apparent. Mean peak injection site
symptom scores increased in a dose-related manner during
both studies (P < 0.0005; linear least-squares regression
excluding the placebo group). In contrast, mean peak systemic
symptom scores failed to exhibit a relationship to dose in either
study. Commercially available subvirion vaccine induced reac-
tion frequencies and severity scores similar to those of the
trivalent HA vaccines at all doses and the high-dose monova-
lent HA vaccine.
Three subjects reported severe symptoms after vaccination
with monovalent HA. In two of them (one given 45 jig and one
given 135 jig), transient headache reported as severe by the
subjects was the only symptom, and in both persons, the
headache responded promptly to over-the-counter analgesics.
The other severe reaction occurred in a subject given a 45-jig
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TABLE 1. Clinical responses during the 2 days after immunization with purified influenza virus HA vaccines
% With injection site reaction: Mean symptom score
Vaccine and dose No. studied Pain or Redness or swelling
tenderness .5 mm in diam. Injection site Systemic
Monovalent HA (study 1)'
0 jig 24 42 0 0.5 0.1
15 jig 30 33 0 0.4 0.2
45 jg 29 55 0 0.6 0.7
135,g 30 63 0 0.9 0.4
405 jg 25 92 12 1.7 0.2
Trivalent HA (study 2)b
0 jig 29 52 0 0.6 0.2
15 jig/strain 27 85 8 1.0 0.3
45 jig/strain 28 96 14 1.3 0.6
135 jig/strain 26 100 4 1.7 0.6
Subvirion vaccine (15 jig of HA/strain [study 2]) 29 97 7 1.0 0.5
a A/Taiwan (H1N1) virus.
b A/Taiwan (H1N1) virus, A/Shanghai (H3N2) virus, and B/Yamagata virus.
reaction was characterized by transient fever of 101F (38.3°C)
and symptoms of an acute upper respiratory illness beginning
several hours after vaccination. One subject each also reported
severe symptoms after receipt of trivalent HA vaccine contain-
ing 45 and 135 jg of HA per strain. In the first case, severe
fatigue was reported during the day after inoculation; an area
(3 by 3.5 cm) of erythema and induration at the injection site
was also observed on this volunteer at the time of examination
on day 2. The second subject reported severe local tenderness
on the day after inoculation, but tenderness elicited by the
examiner was minimal; no medications were required, and the
reaction did not interfere with the subject's activity. Thus,
despite the dose-related increase in local symptoms and an
occasional report of a severe symptom, even the highest doses
of purified HA vaccine were well tolerated.
Antibody responses. (i) Monovalent HA (study 1). All
subjects with low prestudy levels of antibody versus influenza
A/Taiwan (HlNl) virus developed fourfold or greater rises in
both HAI and neutralizing serum antibody titers after vacci-
nation, whereas the frequencies of significant antibody re-
sponses in subjects with high prestudy levels of serum antibody
increased in a dose-related fashion (Table 2). In the latter
subjects, fourfold or greater rises in serum HAI antibody titers
were elicited in 53 to 100% of subjects given 15- to 405-jig
doses of HA, respectively (P < 0.005; chi-square test for linear
trend), while frequencies of significant neutralizing antibody
titer rise ranged between 50% and 93% (P < 0.007; chi-square
test for linear trend).
Geometric mean serum HAI and neutralizing antibody
levels elicited by immunization with the ascending doses of
purified monovalent influenza A/Taiwan virus HA (range, 15
to 405 jig) are shown in Table 2. A significant dose response in
serum HAI antibody levels was observed 2 and 4 weeks after
vaccination (P < 0.05; linear least-squares regression of titer
on dose) but not at 14 or 24 weeks. However, for serum
neutralizing antibody, a significant dose response in mean
titers was observed at each time point during the 6-month
period of study for both the low- and high-antibody groups (P
< 0.01; linear least-squares regression of titer on dose).
The effects of vaccine dose and preimmunization antibody
levels were analyzed with a multiple regression analysis. The
mean titer of antibody elicited directly correlated with the
preimmunization level of antibody when controlling for dose
(P < 0.03 for HAI and neutralizing antibody at 2, 4, 14, and 24
weeks). For subjects with preimmunization levels of 16 or less,
a 27-fold increase in HA dose induced a 2- to 5-fold increase
in serum HAI titer 4 weeks after immunization. Serum neu-
tralizing antibody responses exhibited a similar pattern. Similar
dose-response patterns were observed when controlling for
preimmunization levels of antibody.
The frequencies of fourfold or greater rise in percentage of
HA-specific antibodies between preinoculation and 2 weeks
postinoculation in NW samples collected from subjects given
ascending doses of monovalent A/Taiwan (HlNl) virus HA
are shown in Table 3. A significant increase in response
frequencies of both IgA and IgG antibodies with increasing
vaccine dose was observed (P < 0.0001 for both; chi-square
test for linear trend). In general, the proportions of subjects
with significant rises in percentage of HA-specific antibody
levels were higher in the low-antibody group than in the
high-antibody group when controlling for dose. Two immu-
nized subjects developed significant NW antibody responses
(one with IgA and IgG rises and one with an IgG rise only) in
the absence of a serum antibody response; both were in the
group with high prestudy serum antibody levels. Fifteen sub-
jects had detectable serum antibody responses with neither an
IgG nor an IgA antibody response in NW (7 in the high-
antibody group and 8 in the low-antibody group); 14 of these
15 were given one of the lower doses of vaccine (15 or 45 jig
[data not shown]).
(ii) Trivalent HA (study 2). Serum HAI and neutralizing
antibody responses against the three vaccine viruses were
similar at all postvaccination times for groups given standard
subvirion vaccine or the comparable purified HA vaccine
containing 15 jig of HA per strain (P > 0.05; Student's t test)
(Table 2, trivalent HA). Responses that were significantly
greater than those of the 15-jig dose of HA are noted in the
table.
Turning to individual components of the trivalent vaccine,
serum antibody response patterns versus influenza A/Taiwan
(HlNl) virus after immunization with ascending doses of
purified trivalent HA vaccine (range, 15 to 135 jig per strain
per dose) were similar to those observed after immunization
with monovalent influenza A/Taiwan (HlNl) virus HA. Sig-
nificant correlation of the increases in serum HAI antibody
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TABLE 2. Serum antibody responses after immunization with subvirion influenza virus vaccine or ascending
doses of purified influenza virus HA
HAI antibody response Neutralizing antibody response
Study Vaccine virus Dose (,ug) Geometric mean titer % With Geometric mean titer % Withof HAa at indicated wk >4-fold at indicated wk >4-fold
0 2 4 14 24 rise 0 2 4 14 24 rise
Monovalent HA A/Taiwan (HlNl) 15 (14) 6 97 97 74 52 100 23 1,448 1,552 724 776 100
(study 1) (low-antibody group) 45 (14) 7 169 137 119 97b 100 20 2,521 2,353 1,663 1,176 100
135 (15) 6 147 158 74 64 100 14 2,896 2,195 1,552 891 100
405 (14) 6 315 208 119 69 100 11 6,208 4,390b 2,702b 2,353 100
A/Taiwan (HlNl) 15 (15) 42 97 128 84 69 53 549 1,351 1,552 955 1,024 50
(high-antibody group) 45 (15) 39 274b 294b 256" 169" 87 388 4,096b 3,822" 3,104b 3,327b 73
135 (15) 37 223b 274" 169 111 87 274 3,566b 2,896 2,195" 2,896b 93
405 (10) 34 315" 239 208b 128 100 294 5,405" 4,705" 3,822" 3,327b 90
Trivalent HA A/Taiwan (HlNI) Subvirionc (29) 20 61 64 59 50 55 133 781 867 714 653 62
(study 2) 15 (27) 17 64 66 52 43 63 123 1,201 982 855 724 78
45 (28) 14 121" 100" 70 49 86 130 2,402" 1,808" 1,389 969 75
135 (26) 16 137" 108" 86" 62 73 70 1,499 1,468 1,105 781 81
A/Shanghai (H3N2) Subvirion 11 40 34 29 25 62 36 272 204 236 207 66
15 8 33 25 24 21 63 24 212 208 163 160 78
45 11 59" 49" 33 24 68 35 560" 465" 333 251 93
135 7 84" 56" 33 24 85 32 792" 505" 302 324 92
B/Yamagata Subvirion 5 27 23 22 19 66 10 223 202 153 142 83
15 5 28 27 21 17 70 7 152 124 108 103 78
45 5 36 28 17 14 86 5 271 179 202 144 89
135 4 29 22 14 13 88 5 145 104 59 66 100
a See Materials and Methods for description. n, number of subjects enrolled with at least one postimmunization blood sample.
b Significantly greater than the geometric mean titer elicited by the 15-jLg dose (pooled-variance two-tailed t test).
' Commercial subvirion vaccine contained 15 ,ug of HA per strain per dose.
2 weeks and 14 weeks after inoculation (P < 0.02; linear
least-squares regression of titer on dose). A significant dose
response in serum neutralizing antibody levels was detected
only at the 4-week time point when controlling for the preim-
munization antibody level (P = 0.047; multiple regression
analysis).
Significant dose-response relationships at 2 and 4 weeks
were observed for both serum HAI and neutralizing antibody
responses against influenza A/Shanghai (H3N2) virus after
immunization with purified trivalent HA (15 to 135 ,ug per
dose). Two- to threefold increases in geometric mean HAI
titers in sera collected 4 weeks after immunization were
observed for subjects given up to a ninefold increase in the
dose of purified HA when controlling for the preimmunization
TABLE 3. Antibody responses in nasal secretions after
intramuscular immunization with purified influenza
A/Taiwan (HlNl) virus HA
No./total (%) with rise ina:
Dose of Low-antibody group High-antibody group
IgA IgG IgA IgG
0 0/20 (0) 0/20 (0)
15 6/12 (50) 8/12 (67) 3/14 (21) 5/14 (36)
45 8/14 (57) 9/14 (64) 4/13 (31) 9/13 (69)
135 11/13 (85) 13/13 (100) 7/12 (58) 12/12 (100)
405 9/10 (90) 10/10 (100) 4/7 (57) 6/7 (86)
a Values reflect numbers of subjects with fourfold or greater rise in percentage
of HA-specific antibody as determined with an ELISA.
serum antibody level. Most volunteers with low levels of
preimmunization antibody versus A/H3N2 virus developed
significant serum antibody responses; the frequencies of rise in
those with preimmunization serum HAI antibody levels of 16
or greater were 38% in the group given 15 ,ug and 60% in those
given 135 ,ug of influenza A/Shanghai virus HA in a trivalent
vaccine (data not shown).
A dose-related increase in frequencies of significant serum
antibody responses to B/Yamagata virus was also observed
after administration of purified trivalent HA vaccines, al-
though this dose response was not reflected in geometric mean
serum antibody titers (Table 2, trivalent HA).
DISCUSSION
These studies demonstrate that purified influenza virus HA
vaccine is well tolerated when given intramuscularly in doses of
up to 405 ,ug of HA. Increasing the dose of purified influenza
A/HlN1 and A/H3N2 virus HA resulted in significant in-
creases in serum antibody titers. These enhanced serum anti-
body responses were associated with enhanced nasal secretory
antibody responses in subjects given the monovalent A/HlN1
virus vaccine. The levels of serum antibody achieved after
immunization were directly correlated with preimmunization
levels. Failure to elicit significant antibody responses to stan-
dard doses of HA in subjects with high preexisting levels of
serum antibody could be overcome by increasing the dose of
vaccine.
A number of factors may influence the frequency and
magnitude of serum antibody response after parenteral immu-
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health, prior infection or immunization (priming), type and
dose of vaccine, and preexisting antibody level. The effect of
dose on serum antibody responses to whole virus and subunit
influenza vaccines has been investigated previously. In general,
small increments in dose (less than or equal to two- to
fourfold) fail to elicit significantly higher levels of serum
antibodies (5, 8, 13, 20, 21, 27). Higher increments (10-fold or
greater than standard doses) consistently have been shown to
enhance serum antibody responses (15, 16, 18, 19, 23), al-
though the slope of the dose-response curve is rather flat.
Enhanced protection against naturally occurring influenza
virus was observed after administration of higher doses of
vaccine to prisoners (15, 25) and members of a retirement
community (25).
Although increasing the dose of influenza virus vaccine can
improve antibody responses, the administration of high doses
of vaccine can be associated with increased frequencies of
adverse reactions. Mostow et al. reported a clear relationship
between dose of vaccine and the occurrence of local reactions
after subcutaneous injection (via jet injector gun) of zonal
purified influenza A/Japan/305/57 (H2N2) virus vaccine in the
range of 300 to 4,800 chick cell agglutinating (CCA) units per
dose (19). The frequency of local reactions was markedly
reduced when similar or higher doses of subunit vaccine were
given intramuscularly (23). Adverse effects, including fatigue,
malaise, and fever, were noted to occur more frequently in a
group of soldiers accidently given 10 times the standard dose in
a whole virus vaccine containing 210 ,ug of hemagglutinin than
in a control group given the standard dose (18); the frequency
of local reactions was not reported.
The effect of increasing the dose of vaccine on nasal
secretory antibody responses is less completely characterized
than that for serum antibody. Ruben and colleagues measured
NW neutralizing antibody responses in young adult volunteers
given low (400-CCA-unit) and high (6,400-CCA-unit) doses of
tri-(n-butyl) phosphate-split influenza A/Aichi/68 (H3N2) vi-
rus vaccine intramuscularly (24). The frequency of NW anti-
body response was 77% in the high-dose group compared with
36% in the low-dose group. Similar results occurred with an
influenza A2/Japan/305/57 virus vaccine: 40% of subjects given
300 CCA units intramuscularly developed NW neutralizing
antibodies after immunization, compared with 80% of those
given 4,800 CCA units (19). The frequencies of NW IgG and
IgA antibody responses in the present study exhibited a
dose-related pattern similar to those reported previously,
despite differences in vaccine type and the methods used for
detection of NW antibodies.
Because mucosal antibody can contribute to protection
against influenza virus infection, it seems reasonable to suggest
that the optimal vaccination strategy for prevention of influ-
enza should elicit both local and systemic immune responses.
Several reports have shown that live influenza viruses admin-
istered as nose drops are superior to standard doses of
inactivated vaccines administered parenterally with regard to
their ability to elicit nasal secretory antibody responses (4, 10,
17). In most studies, the frequencies of NW IgA antibody
responses were higher after intranasal vaccination with live
attenuated influenza virus vaccines than after intramuscular
immunization with low doses (15 to 20 ,ug) of inactivated
vaccine (10, 11, 30). Standard doses of inactivated vaccines
given intramuscularly typically elicit NW IgG antibody re-
sponses in about one-third to one-half of adults (4, 10, 11, 26),
although over 90% of subjects with low preinoculation levels of
antibody developed NW IgG antibody responses after a stan-
dard dose of ether-treated vaccine given intramuscularly in one
study (4). The pattern of NW IgG response after intranasal
vaccination with live virus is variable. Inactivated vaccine given
intranasally elicits more secretory antibody responses than
when given intramuscularly, but serum antibody responses in
volunteers vaccinated intranasally are significantly lower (29,
30). Our data demonstrate that the frequencies of NW anti-
body responses (IgG and IgA) after intramuscular immuniza-
tion can approach those achieved after intranasal vaccination
with either live or inactivated vaccine by increasing the dose
administered.
Inactivated influenza virus vaccines are currently recom-
mended for groups of high-risk people without regard to their
various levels of antibody to vaccine viruses. For persons with
intermediate to high levels of preexisting antibody, commer-
cially available vaccines often fail to elicit significant serum
and/or nasal secretory antibody responses. Our data suggest
that increasing the dose with a purified HA vaccine is a
promising approach for the development of improved vaccines
for the prevention of influenza and provide a rationale for
evaluating the use of high-dose vaccines in the elderly.
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